Evidence map›Paper›PMID 25906147›Full record

ArticlePloS one2015

Identification of a receptor for extracellular renalase.

Ling Wang, Heino Velazquez, John Chang, Robert Safirstein, Gary V Desir

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Renalase stimulates aldosterone production via PMCA4b/cAMP in NCI-H295R cells.Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Renalase alleviates salt-induced kidney necroptosis and inflammation.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Article
  9. Renalase peptides reduce pancreatitis severity in mice.American journal of physiology. Gastrointestinal and liver physiology · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Renalase: a novel regulator of cardiometabolic and renal diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients.International journal of environmental research and public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Ling WangDepartment of Medicine, VACHS, Yale University, New Haven, Connecticut, United States of America; Renal Division, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Heino VelazquezDepartment of Medicine, VACHS, Yale University, New Haven, Connecticut, United States of America.
John ChangDepartment of Medicine, VACHS, Yale University, New Haven, Connecticut, United States of America.
Robert SafirsteinDepartment of Medicine, VACHS, Yale University, New Haven, Connecticut, United States of America.
Gary V DesirDepartment of Medicine, VACHS, Yale University, New Haven, Connecticut, United States of America.
VA Caribbean Healthcare System · PRYale University · US

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
The Molecular Physiology of RenalaseR01DK081037 · NIDDK · YALE UNIVERSITY · PI DESIR, GARY V. · 2009 to 2010
$646k
RENALASE DEFICIENCY AND CARDIOVASCULAR COMPLICATIONS OF CHRONIC KIDNEY DISEASERC1DK086402 · NIDDK · YALE UNIVERSITY · PI DESIR, GARY V. · 2010 to 2010
$500k
RENALASE IN ACUTE KIDNEY INJURY: UTILITY AS A BIOMARKER, AND THERAPEUTIC AGENTRC1DK086465 · NIDDK · YALE UNIVERSITY · PI DESIR, GARY V. · 2010 to 2010
$500k
NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK081037NIDDK NIH HHS R01DK081037NIDDK NIH HHS RC1 DK086402NIDDK NIH HHS RC1DK086402NIDDK NIH HHS RC1 DK086465NIDDK NIH HHS RC1DK086465
6 · The paper itself

Abstract

backgroundAn increased risk for developing essential hypertension, stroke and diabetes is associated with single nucleotide gene polymorphisms in renalase, a newly described secreted flavoprotein with oxidoreductase activity. Gene deletion causes hypertension, and aggravates acute ischemic kidney (AKI) and cardiac injury. Independent of its intrinsic enzymatic activities, extracellular renalase activates MAPK signaling and prevents acute kidney injury (AKI) in wild type (WT) mice. Therefore, we sought to identity the receptor for extracellular renalase. METHODS AND

resultsRP-220 is a previously identified, 20 amino acids long renalase peptide that is devoid of any intrinsic enzymatic activity, but it is equally effective as full-length recombinant renalase at protecting against toxic and ischemic injury. Using biotin transfer studies with RP-220 in the human proximal tubular cell line HK-2 and protein identification by mass spectrometry, we identified PMCA4b as a renalase binding protein. This previously characterized plasma membrane ATPase is involved in cell signaling and cardiac hypertrophy. Co-immunoprecipitation and co-immunolocalization confirmed protein-protein interaction between endogenous renalase and PMCA4b. Down-regulation of endogenous PMCA4b expression by siRNA transfection, or inhibition of its enzymatic activity by the specific peptide inhibitor caloxin1b each abrogated RP-220 dependent MAPK signaling and cytoprotection. In control studies, these maneuvers had no effect on epidermal growth factor mediated signaling, confirming specificity of the interaction between PMCA4b and renalase.

conclusionsPMCA4b functions as a renalase receptor, and a key mediator of renalase dependent MAPK signaling.

Indexed as

Acute Kidney InjuryCell LineCytoprotectionDown-RegulationEpidermal Growth FactorEssential HypertensionHumansHypertensionMitogen-Activated Protein KinasesMonoamine OxidasePlasma Membrane Calcium-Transporting ATPasesPolymorphism, Single NucleotideProtein Interaction Domains and MotifsSignal TransductionATP2B4 protein, humanEpidermal Growth FactorMitogen-Activated Protein KinasesMonoamine OxidasePlasma Membrane Calcium-Transporting ATPasesrenalase

Identifiers

PMID25906147
PMCPMC4407985
OpenAlexW2054114473

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.